TEL AVIV, Israel, March 17, 2022 /PRNewswire/ -- SciSparc Ltd.
(NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company
focusing on the development of therapies to treat disorders of the
central nervous system (the "Company" or "SciSparc"), today
announced positive results from a pre-clinical trial as part of its
ongoing collaboration agreement with Clearmind Medicine Inc. (CSE:
CMND), (OTC: CMNDF), (FSE: CWY0). Results showed a
significant dose dependent effect for the MEAI treatment in
reducing alcohol consumption of the treated animals, with
additional significant effect for the CannAmide™ treatment at
the lower sub-effective MEAI dose.
Results showed that alcohol consumption was significantly
reduced following treatment with MEAI at a dose of 40 mg/kg and at
higher doses (p<0.01;) compared to consumption before treatment.
Alcohol consumption was significantly reduced following dual
treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of
20 mg/kg and compared to consumption before treatment. The mice
were provided with 20% alcohol solution, for 24 hours, three times
a week, for 7 weeks, and were treated everyday with MEAI or
MEAI/CannAmide™ during the last two weeks of alcohol
treatment. The alcohol consumption was measured by weighing the
alcohol bottles before and after; water consumption was measured
similarly in parallel.
Oz Adler, SciSparc's Chief Executive Officer, commented, "We are
excited about these positive results, demonstrating the value added
of achieving efficiency in lower doses. The Company's previous
studies of CannAmide™ confirmed that the addition of
CannAmideTM to various cannabinoids, such as THC
and CBD, reduced the effective dose of the cannabinoid while
maintaining its therapeutic effect. We plan to further explore
opportunities in psychedelics market while we continue pursuing our
current ongoing cannabinoid based clinical
programs".
About SciSparc (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. Our focus is on creating and enhancing a portfolio of
technologies and assets based on cannabinoid pharmaceuticals. With
this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive
cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome,
for the treatment of obstructive sleep apnea and Alzheimer's
disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and status
epilepticus.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses the potential benefits of MEAI
treatment and its potential in reducing alcohol consumption of the
treated animals, with additional significant effect for the
CannAmide™ treatment at the lower sub-effective MEAI dose.
Historic results of scientific research and clinical and
preclinical trials do not guarantee that the conclusions of future
research or trials will suggest identical or even similar
conclusions. Because such statements deal with future events and
are based on SciSparc's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" in SciSparc's
Annual Report on Form 20-F filed with the SEC on March 30,
2021, and in subsequent filings with the U.S. Securities and
Exchange Commission. Except as otherwise required by law, SciSparc
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events or
circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
View original
content:https://www.prnewswire.com/news-releases/scisparc-announces-positive-results-from-psychedelic-based-pre-clinical-trial-301504991.html
SOURCE SciSparc Ltd.